Biosimilars (otherwise termed follow-on-biologics, or FOBs for short) stand for the versions of biopharmaceuticals, which have the resembling but not identical parent molecule, and are created either by living organisms or from living micro-organisms by way of rDNA (recombinant DNA) or supervised gene expression technologies. The approval of Biosimilars occurs via strictly defined regulatory paths based on whether FOBs have shown comparability with their reference substance.
The worldwide Biosimilars Market is anticipated to surpass a EUR 14.9bn mark by end 2018. The major drivers encompass cost efficiency of biosimilars versus their high-priced analogues, the enlarging thirst for biotechnology drugs, imminent biotech drugs’ patent expiries, the planet’s aging population, and the rising frequency of critical illnesses. The illustrious actors on the global Biosimilars stage encompass Biocon, Intas Biopharmaceuticals, Cipla, Biopartners, Hospira, Wockhardt, Teva Pharmaceutical Industries, Sandoz International, amidst others.
The Catalogue’s research reports offer world, region and nation-wise analyses of the Biosimilars Market development over various time periods. The researches are lavish with discussions of the Biosimilars Industry growth rate, structure and capacity. The market trends, growth obstacles/stimulators, key products and those in R&D stage, and more issues are studied in the reports. Additionally, the research reports indicate and profile the leading players and hoped-for entrants, and offer market projections and forecasts.
Publications found:
210
Sort by:
Global Adalimumab Biosimilars Market Growth 2026-2032
US$ 3,660.00
The global Adalimumab Biosimilars market size is predicted to grow from US$ 25620 million in 2025 to US$ 33870 million in 2032; it is expected to grow at a CAGR of 4.1% from 2026 to 2032. Adalimumab,...
September 2026
109 pages
Global Pertuzumab Biosimilars Market Growth 2026-2032
US$ 3,660.00
The global Pertuzumab Biosimilars market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032. Pertuzumab is a recombinant...
September 2026
101 pages
Global Trastuzumab Biosimilars Market Growth 2026-2032
US$ 3,660.00
The global Trastuzumab Biosimilars market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032. Trastuzumab is used for the...
September 2026
96 pages
Biosimilars Market by Drug Class (mAbs [Adalimumab, Infliximab, Rituximab, Trastuzumab], GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2036
US$ 2,970.00
... the forecast period.” The biosimilars market by product, is categorized into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant glycosylated proteins segment is expected ...
September 2026
448 pages
Global Biosimilar and Biologics Market Growth 2026-2032
US$ 3,660.00
The global Biosimilar and Biologics market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032. United States market for B...
August 2026
135 pages
Global Omalizumab Injection Market Growth 2026-2032
US$ 3,660.00
The global Omalizumab Injection market size is predicted to grow from US$ 5246 million in 2025 to US$ 8036 million in 2032; it is expected to grow at a CAGR of 6.4% from 2026 to 2032. Omalizumab injec...
August 2026
81 pages
Global Interchangeable Biosimilars Market Growth 2026-2032
US$ 3,660.00
The global Interchangeable Biosimilars market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032. An interchangeable bios...
August 2026
101 pages
Global Biosimilar Bevacizuma Market Growth 2026-2032
US$ 3,660.00
The global Biosimilar Bevacizuma market size is predicted to grow from US$ 1697 million in 2025 to US$ 3150 million in 2032; it is expected to grow at a CAGR of 9.4% from 2026 to 2032. Bevacizumab is...
July 2026
136 pages
Global Bevacizumab Generics Market Growth 2026-2032
US$ 3,660.00
The global Bevacizumab Generics market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032. Bevacizumab generics refer to...
July 2026
112 pages
Global Omalizumab Biosimilars Market Growth 2026-2032
US$ 3,660.00
The global Omalizumab Biosimilars market size is predicted to grow from US$ 284 million in 2025 to US$ 598 million in 2032; it is expected to grow at a CAGR of 11.7% from 2026 to 2032. In 2025, global...
July 2026
108 pages
Biosimilars and Biologics Market - 2025-2033
US$ 3,400.00
Biosimilars and Biologics Marketis is growing with a CAGR of 14.40% during the forecast period 2026-2035. The Biosimilars and Biologics Market emerges as a key focus in DataM Intelligence latest in-de...
July 2026
51 pages
Oncology Biosimilars Market - 2026-2035
US$ 3,400.00
Oncology Biosimilars Market reached US$ 6.76 billion in 2025 and is expected to reach US$ 50.02 billion by 2035, growing with a CAGR of 18.60% during the forecast period 2026-2035. The Oncology Biosim...
July 2026
46 pages
Biosimilars Market - 2026-2035
US$ 3,400.00
Biosimilars Market reached US$34.57 billion in 2025 and is expected to reach US$ 129.29 billion by 2035, growing with a CAGR of 14.10% during the forecast period 2026-2035. The Biosimilars Market emer...
July 2026
37 pages
South Korea Biosimilar Market Size, Share, Trends and Forecast by Molecule, Indication, Manufacturing Type, and Region, 2026-2034
US$ 2,999.00
The South Korea biosimilar market size reached USD 626.5 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 3,992.3 Million by 2034, exhibiting a growth rate (CAGR) of 22.16...
July 2026
118 pages
Biosimilar Monoclonal Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab, Others), By Application (Oncology, Chronic & Autoimmune Diseases, Others), By Region & Competition, 2021-2031F
US$ 4,500.00
The Global Biosimilar Monoclonal Antibodies Market is projected to expand significantly, rising from USD 5.66 Billion in 2025 to USD 11.54 Billion by 2031, demonstrating a compound annual growth rate...
May 2026
185 pages
Biosimilar Testing and Development Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service Type (Analytical Testing, Clinical Testing), By Molecule Type (Monoclonal Antibodies, Recombinant Hormones, Insulin, Interferons, Enzymes, Others), By Therapeutic Area (Oncology, Autoimmune Diseases, Diabetes, Infectious Diseases, Neurology, Others), By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, Others), By Region & Competition, 2021-2031F
US$ 4,500.00
The Global Biosimilar Testing and Development Services Market is poised for substantial growth, projected to increase from USD 3.73 Billion in 2025 to USD 7.53 Billion by 2031, demonstrating a robust...
May 2026
177 pages
Insulin Biosimilars Market - 2026-2033
US$ 3,400.00
Insulin Biosimilars Market reached US$ 2.5 billion in 2025 and is expected to reach US$ 6.0 billion by 2033, growing with a CAGR of 14.80% during the forecast period 2026-2033. The Insulin Biosimilars...
April 2026
45 pages
US Biosimilars Market - 2025-2033
US$ 1,899.00
US Biosimilars Market reached US$ 8.62 billion in 2024 and is expected to reach US$ 65.62 billion by 2033, growing with a CAGR of 25.50% during the forecast period 2026-2033. The US Biosimilars Market...
April 2026
40 pages
Global Biosimilars Market Size Study and Forecast by Product Class (Monoclonal Antibodies, Recombinant Hormones (EPO, G-CSF), Insulins, Low-Molecular-Weight Heparins, Fusion Proteins & Others), by Indication (Oncology, Autoimmune & Chronic Inflammatory, Metabolic Disorders, Blood & Coagulation Disorders, Others), by End-user (Hospitals, Specialty Clinics, Retail & Mail-Order Pharmacies), by Manufacturing Type (In-house, Contract/Outsourced (CMO/CDMO)), by Expression System (Mammalian Cell (CHO, SP2/0), Microbial (E. coli, Yeast)), by Route of Administration (Intravenous, Sub-cutaneous), and Regional Forecasts 2026-2035
US$ 3,000.00
The biosimilars market comprises biologic products that are highly similar to approved reference biologics, offering equivalent therapeutic efficacy, safety, and quality while providing a cost advanta...
April 2026
285 pages
Europe Biosimilar Market Size, Share, Trends and Forecast by Molecule, Indication, Manufacturing Type, and Country, 2026-2034
US$ 2,999.00
The Europe biosimilar market size was valued at USD 16,233.5 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 62,878.9 Million by 2034, exhibiting a CAGR of 15.75% durin...
April 2026
145 pages
Global Biosimilars Market - 2024-2033
US$ 2,999.00
The Global Biosimilars Market was valued at US$ 30.30 Billion in 2024 and is anticipated to reach US$ 99.3 Billion by 2033, at a CAGR of 0.141 from 2026 to 2032. The report delivers in-depth insights...
February 2026
200 pages
